Inivata to present at the Biotech ShowcaseTM in San Francisco

Inivata to present at the Biotech Showcase^TM in San Francisco

Company will also participate in "Generation Genome and Industrial Strategy: Leveraging UK Leadership in Genomics" Panel

Research Triangle Park, NC and Cambridge, UK, January 4, 2018 -- Inivata, a global clinical cancer genomics company utilizing an industry-leading liquid biopsy platform to transform patient care, today announces that Michael Stocum, CEO of Inivata, will present a company update at the Biotech Showcase(TM) 2018 held in San Francisco 8 - 10 January. The presentation will take place at 11:00 PST on Tuesday, 9 January at the Hilton San Francisco, Union Square.

Michael Stocum will also participate in the Generation Genome and Industrial Strategy: Leveraging UK Leadership in Genomics panel, held in partnership with the UK BioIndustry Association, Genomics England and MedCity. The panel will be held from 14:00 - 14:45 on 8 January at Parc 55, Level 3, Market Street. The panel will bring together representatives from Genomics England, technology partners, SMEs and the venture community to debate the opportunities and challenges that will shape the growth of the UK's genomics industry and its impact worldwide. Inivata is currently collaborating with Genomics England as part of the 100,000 Genomes Project, to assess the quality of blood plasma samples and explore the potential of liquid biopsy to improve disease management and cancer patient outcomes.

-Ends-

About Inivata
Inivata is a global clinical cancer genomics company utilizing a proprietary, industry-leading liquid biopsy platform to transform patient care.  Using a simple blood test (liquid biopsy), the analysis of ctDNA is a new lower-cost, less invasive, highly sensitive method for oncologists to diagnose and monitor cancer progression and treatment. The InVision(TM) liquid biopsy platform is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge, combines industry-leading sensitivity with a select multi-gene panel to provide clinically actionable information to clinicians. Inivata has established collaborations with world-leading cancer centers and academic institutions, and is partnering with pharmaceutical and biotechnology companies.  The Company has a CLIA lab in Research Triangle Park, NC and laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.

Media Contacts:

Consilium Strategic Communications
Chris Gardner/Laura Thornton/ Rosie Phillips  
[email protected]
+44 (0)20 3709 5700

Karen Chandler-Smith
[email protected]
+44 (0)7900 430235